DexCom Inc. reported first‑quarter 2026 revenue of $1.1919 billion, up 15% from $1.048 billion in Q1 2025, and non‑GAAP diluted earnings per share of $0.56, beating the consensus estimate of $0.47 by $0.09. The earnings beat was driven by a 62.9% gross profit margin, up from 56.9% a year earlier, and by disciplined cost management that kept operating expenses in line with revenue growth.
Gross profit rose to $750.3 million, or 62.9% of revenue, compared with $596.2 million, or 56.9%, in Q1 2025. Management attributed the margin expansion to manufacturing efficiencies, the initial benefit from the G7 15‑day sensor, and more normalized freight costs as inventory levels improved. "We reported worldwide revenue of $1.19 billion," said CFO Jereme Sylvain, adding that "gross margin was 63.5% of revenue, reflecting continued manufacturing efficiencies, more normalized freight costs… and initial benefit from the switch over to G7 15 Day."
The company reiterated its full‑year 2026 revenue guidance of $5.16 billion to $5.25 billion, unchanged from the prior outlook, and reaffirmed a non‑GAAP gross profit margin guidance of 63% to 64%. "We are reaffirming our prior revenue guidance of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year," said Sylvain. He also noted that "we are reiterating our previous full‑year non‑GAAP gross profit margin guidance of 63% to 64% and increasing our non‑GAAP operating profit margin guidance and adjusted EBITDA margin guidance to 23% to 23.5% and 31% to 31.5%, respectively." The guidance was maintained in light of potential 50‑100 basis‑point risk from fuel and resin costs and geopolitical uncertainties affecting shipping routes.
Revenue growth was driven by a 11% increase in U.S. sales and a 26% rise in international sales, the latter fueled by a 17% organic gain. The G7 15‑day sensor launch continued to drive new starts, and coverage expansion through Prime Therapeutics added a new payer for type 2 non‑insulin patients. "Dexcom delivered strong revenue growth and margin performance to start the year, reflecting healthy demand for Dexcom CGM and continued operational improvement," said President and CEO Jake Leach. He added, "We will work to build on this momentum throughout 2026 and look forward to highlighting Dexcom's long‑term growth opportunity at our Investor Day in the coming weeks."
Investors reacted to the slightly lower revenue guidance relative to consensus, which tempered enthusiasm despite the earnings beat. The company’s focus on maintaining margin guidance amid fuel and shipping headwinds signals a cautious outlook, while the continued expansion of coverage and the G7 15‑day product line provide a tailwind for future growth.
Overall, DexCom’s Q1 2026 results demonstrate strong demand for its CGM technology, effective cost control, and a solid foundation for continued growth. The company’s ability to sustain margin expansion while navigating geopolitical and cost risks positions it well for the remainder of the year, though investors will watch for any changes in guidance or headwinds that could impact the outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.